Operating Income (Loss) in USD of Regen BioPharma Inc from Q1 2013 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Regen BioPharma Inc quarterly/annual Operating Income (Loss) history and change rate from Q1 2013 to Q2 2025.
  • Regen BioPharma Inc Operating Income (Loss) for the quarter ending 30 Jun 2025 was -$40.8K, a 62.3% increase year-over-year.
  • Regen BioPharma Inc Operating Income (Loss) for the twelve months ending 30 Jun 2025 was -$301K, a 23% increase year-over-year.
  • Regen BioPharma Inc annual Operating Income (Loss) for 2024 was -$417K, a 39.3% increase from 2023.
  • Regen BioPharma Inc annual Operating Income (Loss) for 2023 was -$687K, a 102% decline from 2022.
  • Regen BioPharma Inc annual Operating Income (Loss) for 2022 was -$340K, a 69.2% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Regen BioPharma Inc Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2025 -$301K -$40.8K +$67.2K +62.3% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 -$368K -$113K -$12.3K -12.1% 01 Jan 2025 31 Mar 2025 10-Q 28 May 2025
Q4 2024 -$356K -$61.4K +$61.4K +50% 01 Oct 2024 31 Dec 2024 10-Q 16 May 2025
Q3 2024 -$417K -$85.4K -$26.3K -44.5% 01 Jul 2024 30 Sep 2024 10-K 13 May 2025
Q2 2024 -$391K -$108K -$22.8K -26.8% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025
Q1 2024 -$368K -$101K -$22.2K -28.2% 01 Jan 2024 31 Mar 2024 10-Q 28 May 2025
Q4 2023 -$346K -$123K +$341K +73.5% 01 Oct 2023 31 Dec 2023 10-Q 16 May 2025
Q3 2023 -$687K -$59.1K +$38.7K +39.6% 01 Jul 2023 30 Sep 2023 10-K 13 May 2025
Q2 2023 -$726K -$85.2K -$26.2K -44.6% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$699K -$78.8K -$2.35K -3.07% 01 Jan 2023 31 Mar 2023 10-Q 24 Apr 2024
Q4 2022 -$697K -$464K -$357K -336% 01 Oct 2022 31 Dec 2022 10-Q 19 Jan 2024
Q3 2022 -$340K -$97.8K +$29K +22.9% 01 Jul 2022 30 Sep 2022 10-K 20 Nov 2023
Q2 2022 -$369K -$58.9K -$16.4K -38.6% 01 Apr 2022 30 Jun 2022 10-Q 25 Jul 2023
Q1 2022 -$352K -$76.5K -$63.5K -490% 01 Jan 2022 31 Mar 2022 10-Q 18 Apr 2023
Q4 2021 -$289K -$106K -$87.9K -476% 01 Oct 2021 31 Dec 2021 10-Q 19 Jan 2023
Q3 2021 -$201K -$127K -$108K -571% 01 Jul 2021 30 Sep 2021 10-K 15 Nov 2022
Q2 2021 -$92.9K -$42.5K -$26.2K -160% 01 Apr 2021 30 Jun 2021 10-Q 22 Jul 2022
Q1 2021 -$66.7K -$13K +$26.4K +67% 01 Jan 2021 31 Mar 2021 10-Q 21 Apr 2022
Q4 2020 -$93.1K -$18.5K +$116K +86.3% 01 Oct 2020 31 Dec 2020 10-Q 20 Jan 2022
Q3 2020 -$209K -$18.9K +$171K +90% 01 Jul 2020 30 Sep 2020 10-K 22 Dec 2021
Q2 2020 -$380K -$16.3K +$121K +88.1% 01 Apr 2020 30 Jun 2020 10-Q/A 22 Dec 2021
Q1 2020 -$501K -$39.3K +$191K +83% 01 Jan 2020 31 Mar 2020 10-Q 18 Aug 2021
Q4 2019 -$693K -$135K +$64.1K +32.2% 01 Oct 2019 31 Dec 2019 10-Q 13 Aug 2021
Q3 2019 -$757K -$189K -$216K -809% 01 Jul 2019 30 Sep 2019 10-K 04 Aug 2021
Q2 2019 -$541K -$138K -$12.5K -9.97% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2021
Q1 2019 -$528K -$231K +$217K +48.4% 01 Jan 2019 31 Mar 2019 10-Q 05 Aug 2021
Q4 2018 -$745K -$199K +$681K +77.4% 01 Oct 2018 31 Dec 2018 10-Q 05 Aug 2021
Q3 2018 -$1.43M $26.7K +$792K 01 Jul 2018 30 Sep 2018 10-K 21 Jun 2021
Q2 2018 -$2.22M -$125K +$428K +77.4% 01 Apr 2018 30 Jun 2018 10-Q 24 Oct 2019
Q1 2018 -$2.65M -$448K +$211K +32.1% 01 Jan 2018 31 Mar 2018 10-Q 29 Aug 2019
Q4 2017 -$2.86M -$880K -$346K -64.8% 01 Oct 2017 31 Dec 2017 10-Q 12 Feb 2019
Q3 2017 -$2.51M -$765K -$88.2K -13% 01 Jul 2017 30 Sep 2017 10-K 27 Dec 2018
Q2 2017 -$2.42M -$553K +$318K +36.5% 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018
Q1 2017 -$2.74M -$659K +$60.7K +8.44% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 -$2.8M -$534K +$156K +22.6% 01 Oct 2016 31 Dec 2016 10-Q 27 Jan 2017
Q3 2016 -$2.96M -$677K -$154K -29.4% 01 Jul 2016 30 Sep 2016 10-K 21 Dec 2016
Q2 2016 -$2.8M -$871K -$249K -40.1% 01 Apr 2016 30 Jun 2016 10-Q 01 Aug 2016
Q1 2016 -$2.55M -$720K -$98.5K -15.8% 01 Jan 2016 31 Mar 2016 10-Q 29 Apr 2016
Q4 2015 -$2.46M -$689K -$476K -223% 01 Oct 2015 31 Dec 2015 10-Q 27 Jan 2017
Q3 2015 -$1.98M -$523K -$330K -172% 01 Jul 2015 30 Sep 2015 10-K 21 Dec 2016
Q2 2015 -$1.65M -$621K -$464K -294% 01 Apr 2015 30 Jun 2015 10-Q 01 Aug 2016
Q1 2015 -$1.19M -$621K -$451K -265% 01 Jan 2015 31 Mar 2015 10-Q 29 Apr 2016
Q4 2014 -$734K -$213K -$27.6K -14.8% 01 Oct 2014 31 Dec 2014 10-Q/A 28 Apr 2017
Q3 2014 -$706K -$193K 01 Jul 2014 30 Sep 2014 10-K/A 28 Apr 2017
Q2 2014 -$158K -$83K -111% 01 Apr 2014 30 Jun 2014 10-Q/A 28 Apr 2017
Q1 2014 -$170K -$99.5K -141% 01 Jan 2014 31 Mar 2014 10-Q/A 28 Apr 2017
Q4 2013 -$186K 01 Oct 2013 31 Dec 2013 10-Q 04 Feb 2015
Q2 2013 -$74.8K 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$70.5K 01 Jan 2013 31 Mar 2013 10-Q 05 May 2014

Regen BioPharma Inc Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$417K +$270K +39.3% 01 Oct 2023 30 Sep 2024 10-K 13 May 2025
2023 -$687K -$347K -102% 01 Oct 2022 30 Sep 2023 10-K 13 May 2025
2022 -$340K -$139K -69.2% 01 Oct 2021 30 Sep 2022 10-K 20 Nov 2023
2021 -$201K +$8.55K +4.08% 01 Oct 2020 30 Sep 2021 10-K 15 Nov 2022
2020 -$209K +$547K +72.3% 01 Oct 2019 30 Sep 2020 10-K 22 Dec 2021
2019 -$757K +$669K +46.9% 01 Oct 2018 30 Sep 2019 10-K 04 Aug 2021
2018 -$1.43M +$1.09M +43.2% 01 Oct 2017 30 Sep 2018 10-K 21 Jun 2021
2017 -$2.51M +$446K +15.1% 01 Oct 2016 30 Sep 2017 10-K 27 Dec 2018
2016 -$2.96M -$978K -49.4% 01 Oct 2015 30 Sep 2016 10-K 21 Dec 2016
2015 -$1.98M -$1.27M -180% 01 Oct 2014 30 Sep 2015 10-K 21 Dec 2016
2014 -$706K -$387K -121% 01 Oct 2013 30 Sep 2014 10-K/A 28 Apr 2017
2013 -$320K 01 Oct 2012 30 Sep 2013 10-K 18 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.